重编程
材料科学
Toll样受体
免疫疗法
纳米颗粒
癌症研究
纳米技术
受体
先天免疫系统
兴奋剂
免疫系统
免疫学
生物
医学
细胞
内科学
生物化学
作者
Yun Zhang,Yalan Chen,Jiahao Li,Xueqiong Zhu,Yajing Liu,Xiaoxi Wang,Hongfei Wang,Yu Yao,Yanfeng Gao,Zhenzhen Chen
标识
DOI:10.1021/acsami.1c01453
摘要
Most cancers contain abundant tumor-associated macrophages (TAMs). TAMs usually display a tumor-supportive M2-like phenotype; they promote tumor growth and influence lymphocyte infiltration, leading to immunosuppression. These properties have made TAMs an attractive cancer immunotherapy target. One promising immunotherapeutic strategy involves switching the tumor-promoting immune suppressive microenvironment by reprogramming TAMs. However, clinical trials of M2-like macrophage reprogramming have yielded unsatisfactory results due to their low efficacy and nonselective effects. In this article, we describe the development of M2-like macrophage-targeting nanoparticles (PNP@R@M-T) that efficiently and selectively deliver drugs to 58% of M2-like macrophages, over 39% of M1-like macrophages, and 32% of dendritic cells within 24 h in vivo. Compared with the control groups, administration of PNP@R@M-T dramatically reprogrammed the M2-like macrophages (51%), reduced tumor size (82%), and prolonged survival. Our findings indicate that PNP@R@M-T nanoparticles provide an effective and selective reprogramming strategy for macrophage-mediated cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI